Affymax(R) Receives $30 Million Milestone Payments for Database Lock of Phase ... - MarketWatch (press release) PDF Print
MarketWatch (press release)... to develop and commercialize Hematide(TM)/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.